Dauice Turner, PA
Medical · Andover, KSNPI 1336517887
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 127 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 26 manufacturers, the largest accounting for just 16.5% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,717, more than ten times the $29 reported in 2021.
Across 127 payments — averaging $17.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$358
- Lilly USA, LLC$257
- Amgen$205
- AbbVie$162
- Novo Nordisk$159
- Bayer$149
- plus $884 from 20 others
What the payments were for
- Food & beverage$2,173100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 16 | $358 |
| Lilly USA, LLC | 15 | $257 |
| Amgen | 15 | $205 |
| AbbVie | 15 | $162 |
| Novo Nordisk | 9 | $159 |
| Bayer | 11 | $149 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 7 | $116 |
| Otsuka America Pharmaceutical, Inc. | 6 | $113 |
| Astellas Pharma US Inc | 4 | $76 |
| Sumitomo Pharma America, Inc. | 4 | $74 |
| Organon | 2 | $71 |
| GSK | 3 | $51 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 3 | $46 |
| Pfizer | 3 | $46 |
| Merck | 2 | $40 |
| Abbott | 2 | $38 |
| CSL Behring | 1 | $31 |
| Medtronic | 1 | $30 |
| Sanofi Pasteur Inc. | 1 | $27 |
| Vanda Pharmaceuticals Inc. | 1 | $25 |
| Edwards Lifesciences | 1 | $23 |
| Seqirus USA Inc | 1 | $18 |
| Idorsia Pharmaceuticals US Inc | 1 | $16 |
| Lundbeck LLC | 1 | $15 |
| Axsome Therapeutics, Inc. | 1 | $14 |
| Amneal Pharmaceuticals LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,173 in reported general payments places this provider in the 70th percentile of 205 medical providers in Kansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 66 | $71,915 |
| EliquisApixaban | 75 | $49,775 |
| JanuviaSitagliptin Phosphate | 18 | $17,689 |
| JardianceEmpagliflozin | 17 | $9,487 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 11 | $7,106 |
| Humalog Kwikpen U-100Insulin Lispro | 12 | $3,396 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 34 | $3,138 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 12 | $2,974 |
| Levothyroxine Sodium | 194 | $2,311 |
| PradaxaDabigatran Etexilate Mesylate | 11 | $2,287 |
| Novolog FlexpenInsulin Aspart | 12 | $1,976 |
| Potassium Chloride | 71 | $1,610 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 46 | $1,207 |
| Metoprolol Succinate | 76 | $1,198 |
| SynthroidLevothyroxine Sodium | 27 | $1,195 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $159 | $71,91566 claims |
| PfizerEliquis | $46 | $49,77575 claims |
| MerckJanuvia | $40 | $17,68918 claims |
| GSKTrelegy Ellipta | $51 | $7,10611 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $14 | $2,311194 claims |
| AbbVieSynthroid | $162 | $1,19527 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 205 medical providers in Kansas.
Other medical in Andover
- Emily RegehrAndover$6K
- Rachel EwingAndover$4K
- Charles LandersAndover$2K
- Linly StevensOverland Park$111K
- Shana ArnholdShawnee$82K
- Richard AllenbachWichita$70K
- Laura LudlowTopeka$61K
- Anita KishOlathe$58K
- Kathryn WelchWichita$32K
- Courtney SteneOverland Park$22K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.